BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
1
N. H. Nguyen, P. VuTien, R. T. Garcia, H. Trinh, H. Nguyen, K. Nguyen, B. Levitt, M. H. Nguyen. Response to pegylated interferon and ribavirin in Asian American patients with Chronic hepatitis C genotypes 1 vs 2/3 vs 6Journal of Viral Hepatitis 2010; 17(10): 691 doi: 10.1111/j.1365-2893.2009.01226.x
2
Giuseppe Indolfi, Giusi Mangone, Elisa Bartolini, Gabriella Nebbia, Pier Luigi Calvo, Maria Moriondo, Pier-Angelo Tovo, Maurizio de Martino, Chiara Azzari, Massimo Resti, David R. Booth. Comparative Analysis of rs12979860 SNP of the IFNL3 Gene in Children with Hepatitis C and Ethnic Matched Controls Using 1000 Genomes Project DataPLoS ONE 2014; 9(1): e85899 doi: 10.1371/journal.pone.0085899
3
Gautam Ray. Factors affecting outcome of treatment of chronic hepatitis C: result of an open label study from eastern IndiaTropical Doctor 2016; 46(1): 28 doi: 10.1177/0049475515569519
4
Muhammad Imran, Sobia Manzoor, Sikandar Azam, Saleha Resham. Genetic variant ofIL28Brs12979860, as predictive marker of interferon-based therapy in Pakistani populationAPMIS 2015; 123(4): 342 doi: 10.1111/apm.12365
5
K. Muller, A. Rodgers, R. Wundke, V. Waddell, R. Altus, D. L. Gordon, A. Wigg. Single centre experience with pegylated interferon and ribavirin for hepatitis C: looking back before moving forwardInternal Medicine Journal 2012; 42(7): 765 doi: 10.1111/j.1445-5994.2012.02798.x
6
Philip Vutien, Nghia H Nguyen, Huy N Trinh, Jiayi Li, Ruel T Garcia, Gabriel Garcia, Khanh K Nguyen, Huy A Nguyen, Brian S Levitt, Emmet B Keeffe, Mindie H Nguyen. Similar Treatment Response to Peginterferon and Ribavirin in Asian and Caucasian Patients With Chronic Hepatitis CAmerican Journal of Gastroenterology 2010; 105(5): 1110 doi: 10.1038/ajg.2009.635
7
Huy Anh Tran, Glenn Edward Malcolm Reeves, Robert Gibson, John Richard Attia. Development of thyroid diseases in the treatment of chronic hepatitis C with α-interferon may be a good prognosticator in achieving a sustained virological response: A meta-analysisJournal of Gastroenterology and Hepatology 2009; 24(7): 1163 doi: 10.1111/j.1440-1746.2009.05874.x
8
Jacinta A Holmes, William Sievert, Alexander J Thompson. IL28Bpolymorphism and genetic biomarkers of viral clearance in hepatitis C virus infectionBiomarkers in Medicine 2011; 5(4): 461 doi: 10.2217/bmm.11.47
9
Kenneth Kar-Lung Yan, Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Henry Lik-Yuen Chan. Rate and Factors Affecting Treatment Uptake of Patients with Chronic Hepatitis C in a Tertiary Referral HospitalDigestive Diseases and Sciences 2010; 55(12): 3541 doi: 10.1007/s10620-010-1412-1
10
Huy A Tran, Tracey L Jones, Robert Gibson, Glenn EM Reeves. Thyroid disease is a favorable prognostic factor in achieving sustained virologic response in chronic hepatitis C undergoing combination therapy: A nested case control studyBMC Endocrine Disorders 2011; 11(1) doi: 10.1186/1472-6823-11-10
11
Siddapuram Sivaprasad, Padaki Nagaraja Rao, Rajesh Gupta, Kaitha Ashwini, Duvvuru Nageshwar Reddy. The Distribution of Genotype and Allelic Frequency of IL28B Gene Polymorphism in Andhra Pradesh, IndiaJournal of Clinical and Experimental Hepatology 2012; 2(2): 112 doi: 10.1016/S0973-6883(12)60098-X
12
Hu Li, Jia-Li Tan, Jian-Rui Li, Nan-Nan Liu, Jin-Hua Chen, Xiao-Qin Lv, Li-li Zou, Biao Dong, Zong-Gen Peng, Jian-Dong Jiang. A proof-of-concept study in HCV-infected Huh7.5 cells for shortening the duration of DAA-based triple treatment regimensBiomedicine & Pharmacotherapy 2019; 116: 108976 doi: 10.1016/j.biopha.2019.108976
13
Mario Frias, Antonio Rivero-Juárez, Pedro López-López, Antonio Rivero. Pharmacogenetics and the treatment of HIV-/HCV-coinfected patientsPharmacogenomics 2018; 19(12): 979 doi: 10.2217/pgs-2018-0046
14
Thomas Urban, Michael R. Charlton, David B. Goldstein. Introduction to the genetics and biology of interleukin-28BHepatology 2012; 56(1): 361 doi: 10.1002/hep.25794
15
Albert Friedrich Stättermayer, Rudolf Stauber, Harald Hofer, Karoline Rutter, Sandra Beinhardt, Thomas Matthias Scherzer, Kerstin Zinober, Christian Datz, Andreas Maieron, Emina Dulic–Lakovic, Harald H. Kessler, Petra Steindl–Munda, Michael Strasser, Christoph Krall, Peter Ferenci. Impact of IL28B Genotype on the Early and Sustained Virologic Response in Treatment-Naïve Patients With Chronic Hepatitis CClinical Gastroenterology and Hepatology 2011; 9(4): 344 doi: 10.1016/j.cgh.2010.07.019
16
Sabela Lens García, Mairene Coto-Llerena, Sofía Pérez del Pulgar Gallart, Xavier Forns Bernhardt. Genética y tratamiento de la hepatitis C: ¿hacia un tratamiento personalizado?Gastroenterología y Hepatología 2011; 34(5): 352 doi: 10.1016/j.gastrohep.2010.12.008
17
Paul J Clark, Alex J Thompson, John G McHutchison. IL28B Genomic-Based Treatment Paradigms for Patients With Chronic Hepatitis C Infection: The Future of Personalized HCV TherapiesAmerican Journal of Gastroenterology 2011; 106(1): 38 doi: 10.1038/ajg.2010.370
18
Nae-Yun Heo, Young-Suk Lim, Han Chu Lee, Yung Sang Lee, Kang Mo Kim, Kwan Soo Byun, Kwang-Hyub Han, Kwan Sik Lee, Seung Woon Paik, Seung Kew Yoon, Dong Jin Suh. High effectiveness of peginterferon alfa-2a plus ribavirin therapy in Korean patients with chronic hepatitis C in clinical practiceClinical and Molecular Hepatology 2013; 19(1): 60 doi: 10.3350/cmh.2013.19.1.60
19
Arghavan Haj-sheykholeslami, Maryam Keshvari, Heidar Sharafi, Ali Pouryasin, Khalil Hemmati, Fatemeh Mohammadzadehparjikolaei. Interferon-λ polymorphisms and response to pegylated interferon in Iranian hepatitis C patientsWorld Journal of Gastroenterology 2015; 21(29): 8935-8942 doi: 10.3748/wjg.v21.i29.8935
20
Mahtab Daneshvar, Mehri Nikbin, Solmaz Talebi, Foozieh Javadi, Mohammad Reza Aghasadeghi, Sanaz Mahmazi, Seyed Mehdi Sadat. Role of IL28-B Polymorphism (rs12979860) on Sustained Virological Response to Pegylated Interferon/Ribavirin in Iranian Patients With Chronic Hepatitis CIranian Red Crescent Medical Journal 2016; 18(9) doi: 10.5812/ircmj.28566
21
L. H. Nguyen, M. H. Nguyen. Systematic review: Asian patients with chronic hepatitis C infectionAlimentary Pharmacology & Therapeutics 2013; 37(10): 921 doi: 10.1111/apt.12300
22
BYM Soh, R Kumar, VSM Ekstrom, CYH Lin, S Thangaraju, HH Tan, KP Chan, LHL Choong, D Teo, WC Chow. Prevalence of hepatitis C virus infection and the IL28B genotype polymorphism among blood donors and high-risk populationsSingapore Medical Journal 2019; 60(1): 34 doi: 10.11622/smedj.2018078
23
Dongliang Ge, Jacques Fellay, Alexander J. Thompson, Jason S. Simon, Kevin V. Shianna, Thomas J. Urban, Erin L. Heinzen, Ping Qiu, Arthur H. Bertelsen, Andrew J. Muir, Mark Sulkowski, John G. McHutchison, David B. Goldstein. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearanceNature 2009; 461(7262): 399 doi: 10.1038/nature08309
24
Dong-Won Kim, Seoung-Ae Lee, Hong Kim, You-Sub Won, Bum-Joon Kim, Jason Blackard. Naturally Occurring Mutations in the Nonstructural Region 5B of Hepatitis C Virus (HCV) from Treatment-Naïve Korean Patients Chronically Infected with HCV Genotype 1bPLoS ONE 2014; 9(1): e87773 doi: 10.1371/journal.pone.0087773
25
LI-SHENG WU, HONG WANG, XIAO-PING GENG. Two IL28B polymorphisms are associated with the treatment response of different genotypes of hepatitis C in different racial populations: A meta-analysisExperimental and Therapeutic Medicine 2012; 3(2): 200 doi: 10.3892/etm.2011.385
26
Ajit Sood, Vandana Midha, Omesh Goyal, Syed Hissar, Suresh Kumar Sharma, Pankaj Khanna. Treatment of chronic hepatitis C with pegylated interferon plus ribavirin in treatment-naïve ‘real-life’ patients in IndiaIndian Journal of Gastroenterology 2014; 33(4): 343 doi: 10.1007/s12664-014-0451-5
27
Ashwin Balagopal, David L. Thomas, Chloe L. Thio. IL28B and the Control of Hepatitis C Virus InfectionGastroenterology 2010; 139(6): 1865 doi: 10.1053/j.gastro.2010.10.004
28
Lourianne Nascimento Cavalcante, Kiyoko Abe-Sandes, Ana Luiza Dias Angelo, Taisa Manuela B. Machado, Denise C. Lemaire, Carlos Maurício Cardeal Mendes, João Renato Pinho, Fernanda Malta, Luiz G.C. Lyra, André Castro Lyra. IL28B polymorphisms are markers of therapy response and are influenced by genetic ancestry in chronic hepatitis C patients from an admixed populationLiver International 2011; : n/a doi: 10.1111/j.1478-3231.2011.02653.x
29
Xiao-Xiao Wang, Bi-Fen Luo, Han-Ji Jiang, Xu Cong, Qian Jin, Dan-Li Ma, Lai Wei, Bo Feng. Recovery of natural killer cells is mainly in post-treatment period in chronic hepatitis C patients treated with sofosbuvir plus ledipasvirWorld Journal of Gastroenterology 2018; 24(40): 4554-4564 doi: 10.3748/wjg.v24.i40.4554
30
Victoria A. Sublette, Mark W. Douglas, Kirsten McCaffery, Jacob George, Kathryn Nicholson Perry. Psychological, lifestyle and social predictors of hepatitis C treatment response: a systematic reviewLiver International 2013; 33(6): 894 doi: 10.1111/liv.12138
31
Wangxia Tong, Jianyun Zhu, Ning Luo, Xiaohua Yang, Zhiying Lei, Xiaoliang Huang, Zhixin Zhao, Xiaohong Zhang, Zhiliang Gao, Zhonghua Jiang. Response to Pegylated Interferon Plus Ribavirin in Patients with Hepatitis C Virus Genotype 6a Infection from Guangdong and Guangxi Province of ChinaGastroenterology Research and Practice 2016; 2016: 1 doi: 10.1155/2016/5397407